BRAIN Biotech AG announces the appointment of Erik de Vries as Senior
Business Development Director Enzymes

EQS-News: BRAIN Biotech AG / Key word(s): Personnel
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior
Business Development Director Enzymes

29.05.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

BRAIN Biotech AG announces the appointment of Erik de Vries as Senior
Business Development Director Enzymes

Zwingenberg and Greifswald, May 29, 2024 - BRAIN Biotech AG and Enzymicals
AG are pleased to announce that Dr. Erik de Vries will join BRAIN Biotech as
Senior Business Development Director Enzymes as of June 1st, 2024. De Vries
will continue in his current position as CEO of Enzymicals AG on a part-time
basis during a transition phase until the end of the year. During this
transition phase, his activities will already focus on BRAIN Biotech at the
Zwingenberg site.

A succession plan is being implemented. A new CEO will take over the duties
from Erik de Vries from January 1st, 2025.

Following the handover of the CEO position at Enzymicals, it is planned to
have Erik de Vries appointed to the Supervisory Board of Enzymicals AG as a
representative of BRAIN Biotech AG at the 2025 Annual General Meeting. This
is to ensure that he can continue to support Enzymicals' growth strategy
with his knowledge and expertise, serving the interests of both Enzymicals
AG as well as BRAIN Biotech AG as one of Enzymicals' shareholders.

Prof. Dr. Uwe Bornscheuer, Chairman of the Supervisory Board of Enzymicals
AG, states: 'Erik de Vries has done an excellent job since he started in
early 2022 as a CEO of Enzymicals as reflected in the record revenues and
numerous new projects being under way. At the Supervisory Board, we are very
grateful for his valuable input thanks to his decades long experience in
biocatalysis and business development. I am confident that Enzymicals will
continue along this path in the future and very much look forward to having
Erik de Vries on the Board from 2025.'

'Enzymicals has come out of the Covid crisis really well over the past
years', says Erik de Vries and continues: 'We have seen record revenue
coming in in 2022 and 2023 and also this year is already tracking towards
achieving a new record revenue. We see a healthy expansion in the customer
base as well as a deepening of existing business relationships. This is
proof that Enzymicals has earned its place in the market. As Senior Director
Business Development at BRAIN Biotech, I will use my expertise to increase
revenues, but I will certainly also be on the lookout for synergies between
our two companies.'

Dr. Martin Langer, Managing Director & Executive Vice President at BRAIN
Biotech AG welcomes Erik de Vries to the BRAIN Biotech family: 'Erik is very
well connected in the enzyme world and deeply understands the benefits of
using our proprietary technology packages such as highly sophisticated
microbial production strains, genome editing tools, as well as the easy
access to novel enzymes through the metagenome libraries. With his deep
insight in markets such as pharma, food, feed and beverages and the
knowledge about the needs of the players in these markets, he is the right
person and a perfect fit to support the business development team of BRAIN
Biotech in Zwingenberg. I am looking forward working together with Erik with
the goals to deepen the synergies between Enzymicals and BRAIN and to
further grow BRAIN Biotech´s tailor made solutions business.'

About Erik de Vries

Erik de Vries has studied Organic Chemistry at the University of Groningen
in The Netherlands. After obtaining his PhD at the same university in 1997
and during 8 years of postdoc, he started his own spin-off company involved
in enzymatic technology. After a successful sale of the company to Codexis
Inc, he moved to California to work at Codexis in various functions with
increasing responsibility. After Codexis, Erik was Technical Sales Manager
for the Americas for the LifeTech(TM) line of resins at Purolite, Regional
Sales Manager North America at the strain engineering company Amyris and
then West Coast Business Development Manager at the Swiss pharma contract
manufacturer Dottikon Exclusive Synthesis AG. After moving back to his home
base in The Netherlands, Erik started his own biotechnology consulting
company and has been involved worldwide in the early stages of numerous
biotech and deep tech start-up initiatives. Erik currently is the CEO of
Enzymicals AG as well as a member of the (Technical) Advisory Boards of
FabricNano Ltd (London, UK) and of Allozymes Pte Ltd (Singapore). Erik has a
large network of connections in the biotech, renewable chemicals, cosmetic
ingredients and pharmaceuticals areas.

+++

About Enzymicals

Enzymicals is your experienced partner for industrial biocatalysis from mg
to ton-scale with 15 years of experience. Enzymicals' experts offer their
recognized expertise in the use of enzymatic processes for complex chemical
synthesis, from initial catalyst-lead finding to process optimization and
scale-up. Combining many years of experience in biotechnology with
state-of-the art facilities, our company has success stories with many
partners from diverse industries speeding up their developments.

For more information: www.enzymicals.com; info@enzymicals.com.

About BRAIN Biotech

BRAIN Biotech AG is a leading European supplier of biobased products and
solutions such as enzymes and proteins, microbial production strains,
natural compounds and biotechnological solutions for more sustainable
industrial processes. The company focuses on the fields of nutrition, health
and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech
Group. The Group's business activities are divided into three segments: The
BioProducts segment comprises the product business with specialty enzymes
and other proteins, for which the Group operates fermentation facilities in
the United Kingdom and production facilities in continental Europe and the
United States. The BioScience segment offers research-intensive custom
solutions based on enzyme technology, strain development, bioprocess
development and natural product screening. The BioIncubator segment conducts
its own R&D projects or those initiated with partners with high value-added
potential. A particularly promising incubator project is the development of
the Company's own CRISPR-based gene editing technology platform, which is
currently being established and expanded by Akribion Genomics (in foundation
planning).

Through its own R&D activities, BRAIN Biotech Group is continuously
expanding its product portfolio in the field of specialty enzymes and small
molecules. The latter are the starting point for screenings, e.g. for novel
drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt
Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities
identification number: ISIN DE0005203947 / WKN 520394). The company employs
approximately 330 people and generated revenues of EUR 55.3 million in the
fiscal year 2022/23.

For more information, please visit: https://www.brain-biotech.com, LinkedIn,
Threads and YouTube.

Contact Media
Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations
Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN Biotech AG, and are based on information currently available to the
management.

Forward-looking statements are no guarantees of future performance, and
entail both known and unknown risks as well as uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. Numerous factors exist that could
influence the future performance of and future developments at BRAIN Biotech
AG and the BRAIN Biotech Group. Such factors include, but are not limited
to, changes in the general economic and competitive environment, risks
associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any
forward-looking statements.


---------------------------------------------------------------------------

29.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        BRAIN Biotech AG
                   Darmstädter Straße 34-36
                   64673 Zwingenberg
                   Germany
   Phone:          +49 (0) 62 51 / 9331-0
   Fax:            +49 (0) 62 51 / 9331-11
   E-mail:         ir@brain-biotech.com
   Internet:       www.brain-biotech.com
   ISIN:           DE0005203947
   WKN:            520394
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1913013

End of News EQS News Service
---------------------------------------------------------------------------

1913013 29.05.2024 CET/CEST